Reumatische ziekten als risicofactoren voor hart- en vaatziekten

M T Nurmohamed; A E Voskuyl; I E van der Horst-Bruinsma; B A C Dijkmans

Reumatische ziekten als risicofactoren voor hart- en vaatziekten

Translated title of the contribution: Rheumatic diseases as risk factors for cardiovascular disease

M T Nurmohamed, A E Voskuyl, I E van der Horst-Bruinsma, B A C Dijkmans

Research output: Contribution to journal › Review article › Academic › peer-review

Abstract

Cardiovascular disease is the leading cause of death in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and systemic lupus erythematosus (SLE). In addition to mortality, cardiovascular morbidity is also markedly increased in these patients, compared with the general population. The increased cardiovascular risk can be explained only partially by an increased prevalence of classical risk factors for cardiovascular disease; it also appears to be related to inflammation. Prospective intervention trials aimed at the modification of cardiovascular risk factors are needed to determine the impact of cardiovascular risk reduction in patients with rheumatic disease. In addition to SLE, RA and AS should be acknowledged as new risk factors for cardiovascular disease.

Translated title of the contribution	Rheumatic diseases as risk factors for cardiovascular disease
Original language	Dutch
Pages (from-to)	1921-4
Number of pages	4
Journal	Nederlands Tijdschrift voor Geneeskunde
Volume	150
Issue number	35
Publication status	Published - 2 Sept 2006

Keywords

Arthritis, Rheumatoid/complications
Cardiovascular Diseases/epidemiology
Comorbidity
Humans
Lupus Erythematosus, Systemic/complications
Rheumatic Diseases/complications
Risk Assessment
Risk Factors
Spondylitis, Ankylosing/complications

Cite this

@article{f912962d3d9a4f6295f56a7e9cf3fe70,

title = "Reumatische ziekten als risicofactoren voor hart- en vaatziekten",

abstract = "Cardiovascular disease is the leading cause of death in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and systemic lupus erythematosus (SLE). In addition to mortality, cardiovascular morbidity is also markedly increased in these patients, compared with the general population. The increased cardiovascular risk can be explained only partially by an increased prevalence of classical risk factors for cardiovascular disease; it also appears to be related to inflammation. Prospective intervention trials aimed at the modification of cardiovascular risk factors are needed to determine the impact of cardiovascular risk reduction in patients with rheumatic disease. In addition to SLE, RA and AS should be acknowledged as new risk factors for cardiovascular disease.",

keywords = "Arthritis, Rheumatoid/complications, Cardiovascular Diseases/epidemiology, Comorbidity, Humans, Lupus Erythematosus, Systemic/complications, Rheumatic Diseases/complications, Risk Assessment, Risk Factors, Spondylitis, Ankylosing/complications",

author = "Nurmohamed, {M T} and Voskuyl, {A E} and {van der Horst-Bruinsma}, {I E} and Dijkmans, {B A C}",

year = "2006",

month = sep,

day = "2",

language = "Dutch",

volume = "150",

pages = "1921--4",

journal = "Nederlands Tijdschrift voor Geneeskunde",

issn = "0028-2162",

publisher = "Vereniging Nederlands Tijdschrift voor Geneeskunde",

number = "35",

}

TY - JOUR

T1 - Reumatische ziekten als risicofactoren voor hart- en vaatziekten

AU - Nurmohamed, M T

AU - Voskuyl, A E

AU - van der Horst-Bruinsma, I E

AU - Dijkmans, B A C

PY - 2006/9/2

Y1 - 2006/9/2

N2 - Cardiovascular disease is the leading cause of death in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and systemic lupus erythematosus (SLE). In addition to mortality, cardiovascular morbidity is also markedly increased in these patients, compared with the general population. The increased cardiovascular risk can be explained only partially by an increased prevalence of classical risk factors for cardiovascular disease; it also appears to be related to inflammation. Prospective intervention trials aimed at the modification of cardiovascular risk factors are needed to determine the impact of cardiovascular risk reduction in patients with rheumatic disease. In addition to SLE, RA and AS should be acknowledged as new risk factors for cardiovascular disease.

AB - Cardiovascular disease is the leading cause of death in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and systemic lupus erythematosus (SLE). In addition to mortality, cardiovascular morbidity is also markedly increased in these patients, compared with the general population. The increased cardiovascular risk can be explained only partially by an increased prevalence of classical risk factors for cardiovascular disease; it also appears to be related to inflammation. Prospective intervention trials aimed at the modification of cardiovascular risk factors are needed to determine the impact of cardiovascular risk reduction in patients with rheumatic disease. In addition to SLE, RA and AS should be acknowledged as new risk factors for cardiovascular disease.

KW - Arthritis, Rheumatoid/complications

KW - Cardiovascular Diseases/epidemiology

KW - Comorbidity

KW - Humans

KW - Lupus Erythematosus, Systemic/complications

KW - Rheumatic Diseases/complications

KW - Risk Assessment

KW - Risk Factors

KW - Spondylitis, Ankylosing/complications

M3 - Review article

C2 - 16999275

SN - 0028-2162

VL - 150

SP - 1921

EP - 1924

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

IS - 35

ER -